Abstract
Only in early stages of HCC resection, local ablative therapy, and transplantation are offering a chance of cure, whereas only a minority of patient will amenable for such a therapy. The majority of patients are presenting an intermediate or even advanced tumor stages where the therapeutic options are limited to transarterial and systemic molecular therapies. Radio embolization may augment the therapeutic armamentarium particularly in patients just not meeting the criteria for resection, percutaneous ablation or transplantation by downsizing/downgrading or in progressed disease where transarterial chemotherapy is contraindicated. Recent results of radio embolization in these settings and future directions will be discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AASLD:
-
American Association for the Study of Liver Diseases
- BCLC:
-
Barcelona-Clinic Liver Cancer
- BSC:
-
Best supportive care
- C-B:
-
Child-Pugh
- CR:
-
Complete response
- EASL:
-
European Association for the Study of the Liver
- ECOG:
-
Eastern Cooperative Oncology Group
- ENRY:
-
European Network on Radioembolization with Yttrium-90 Resin Microspheres
- EORTC:
-
European Organization for Research and Treatment of Cancer
- ESMO:
-
European Society for Medical Oncology
- Gd-EOB-DTPA:
-
Gadoxetic acid (Promovist®, Bayer, Germany)
- LTx:
-
Liver transplantation
- NCCN:
-
National Comprehensive Cancer Network
- NCI:
-
National Cancer Institute
- PR:
-
Partial response
- PVT:
-
Portal-vein thrombosis
- RE:
-
Radio-embolization
- Rx:
-
Resection
- SD:
-
Stable disease
- SHARP:
-
Sorafenib HCC Assessment Randomized Protocol
- TACE:
-
Transarterial chemo-embolization
- TAE:
-
Transarterial embolization
- TTP:
-
Time to progression
- UNOS:
-
United Network for Organ Sharing
- VT:
-
Venous thrombosis
References
Ahmadzadehfar H, Meyer C, Ezziddin S, Sabet A, Hoff-Meyer A, Muckle M, Logvinski T, Schild HH, Biersack HJ, Wilhelm K (2013) Hepatic volume changes induced by radioembolization with (90)Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 40(1):80–90
Anaya DA, Blazer DG, Abdalla EK (2008) Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. Semin Interv Radiol 25(2):110–122
Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022
Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57(4):821–829
Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J (2012) Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 56(6):1330–1335
Carr BI, Kondragunta V, Buch SC, Branch RA (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116(5):1305–1314
Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248(4):617–625
Chaudhury PK, Hassanain M, Bouteaud JM, Alcindor T, Nudo CG, Valenti D, Cabrera T, Kavan P, Feteih I, Metrakos P (2010) Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization. Curr Oncol 17(5):67–69
Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258(2):627–634
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13(1):e11–e22
Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Goin JE (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41(10):1673–1681
D’Avola D, Lnarrairaegui M, Bilbao JI, Martinez-Cuesta A, Alegre F, Herrero JI, Quiroga J, Prieto J, Sangro B (2009) A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 56(96):1683–1688
Denys A, Prior J, Bize P, Duran R, De Baere T, Halkic N, Demartines N (2012) Portal vein embolization: what do we know? Cardiovasc Interv Radiol 35(5):999–1008
Di Sandro S, Giacomoni A, Slim A, Lauterio A, Mangoni I, Mihaylov P, Pirotta V, Aseni P, De Carlis L (2012) Living donor liver transplantation for hepatocellular carcinoma: the impact of neo-adjuvant treatments on the long term results. Hepatogastroenterology 59(114):505–510
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) J Hepatol 56(4): 908–943
Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255
Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, Ryu RK, Sato KT, Gates V, Abecassis MM, Omary RA, Baker TB, Salem R (2009) Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 16(6):1587–1596
Garden OJ (2011) Pushing the limits of surgical management in patients with hepatocellular carcinoma. Br J Surg 98(9):1183–1184
Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA (2011) Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 98(9):1201–1208
Gulec SA, Pennington K, Hall M, Fong Y (2009) Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol 7:6. doi:10.1186/1477-7819-7-6
Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G (2010) Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52(5):1741–1749
Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, Salem R, Lewandowski RJ (2012) Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Interv Radiol 35(5):1094–1101
Inarrairaegui M, Thurston KG, Bilbao JI, D’Avola D, Rodriguez M, Arbizu J, Martinez-Cuesta A, Sangro B (2010) Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 21(8):1205–1212
Inarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D’Avola D, Herrero JI, Rodriguez M, Marti P, Zozaya G, Dominguez I, Quiroga J, Sangro B (2012) Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 38(7):594–601
Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, Miller F, Ryu RK, Ibrahim S, Sato KT, Kulik LM, Mulcahy MF, Omary R, Murthy R, Reiser MF, Salem R (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 53(9):2556–2563
Jelic S and Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v59-v64
Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21(2):224–230
Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Haines KG 3rd, Salem R (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572–586
Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, Li AK (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40(3):583–592
Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9(8):1920–1928
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390
Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M (2011) Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 18(2):413–420
Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchiano A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, and Spreafico C (2012) Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: A phase II study. Hepatology, Accepted Article. doi:10.1002/hep.26014
Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, Riaz A, Gupta R, Vouche M, Gates VL, Miller FH, Omary RA, Salem R (2012) Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. J Hepatol. doi:10.1016/j.jhep.2012.09.003
Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12(8):1260–1267
Raoul JL, Boucher E, Rolland Y, Garin E (2010) Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 7(1):41–49
Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT, Omary RA, Salem R (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185–1193
Rimassa L, Santoro A (2009) Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 9(6):739–745
Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64
Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, 3rd, and Mulcahy MF (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2): 497–507 e2
Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66(3):792–800
Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Inarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S (2011) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3):868–878
Seidensticker R, Seidensticker M, Damm R, Mohnike K, Schutte K, Malfertheiner P, Van Buskirk M, Pech M, Amthauer H, Ricke J (2012) Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Interv Radiol 35(5):1109–1118
Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, Iaccarino G, Benassi M, Ettorre GM, Maini CL (2010) Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 51(9):1377–1385
Theysohn JM, Schlaak JF, Muller S, Ertle J, Schlosser TW, Bockisch A, Lauenstein TC (2012) Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. J Vasc Interv Radiol 23(7):949–952
Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O’Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A (2010) Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28(25):3994–4005
Toso C, Mentha G, Kneteman NM, Majno P (2010) The place of downstaging for hepatocellular carcinoma. J Hepatol 52(6):930–936
Vogl TJ, Nour-Eldin NE, Emad-Eldin S, Naguib NN, Trojan J, Ackermann H, Abdelaziz O (2011) Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 17(10):1267–1275
Woodall CE, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, McMasters KM, Martin RC 2nd (2009) Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 208(3):375–382
Worns MA, Weinmann A, Schuchmann M, Galle PR (2009) Systemic therapies in hepatocellular carcinoma. Dig Dis 27(2):175–188
Wu ZJ, Cai J, Xu AB, Su XQ, Wang XQ, Zhang YX, Shao BF, Li YJ, Chu KY (2011) Combined three-dimensional conformal radiotherapy plus transcatheter arterial chemoembolization and surgical intervention for portal vein tumor thrombus in patients with hepatocelular carcinoma. Zhonghua Yi Xue Za Zhi 91(40):2841–2844
Yoo H, Kim JH, Ko GY, Kim KW, Gwon DI, Lee SG, Hwang S (2011) Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol 18(5):1251–1257
Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ (2012) Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 82(5):2004–2011
Yoshidome H, Takeuchi D, Kimura F, Shimizu H, Ohtsuka M, Kato A, Furukawa K, Yoshitomi H, Miyazaki M (2011) Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion: a single institution experience. J Am Coll Surg 212(5):796–803
Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC (2009) Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer 115(6):1245–1252
Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H (2010) Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 21(3):326–332
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Helmberger, T. (2013). HCC. Radioembolization Combined with Other Therapeutic Local and Systemic Treatment. In: Bilbao, J., Reiser, M. (eds) Liver Radioembolization with 90Y Microspheres. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2013_821
Download citation
DOI: https://doi.org/10.1007/174_2013_821
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-36472-3
Online ISBN: 978-3-642-36473-0
eBook Packages: MedicineMedicine (R0)